Other Events ·
Emergent BioSolutions Inc. filed a Form 8-K to furnish an investor presentation by CEO Joseph C. Papa at the H.C.…
EBSEmergent BioSolutions Inc.
Emergent BioSolutions Inc. filed a Form 8-K to furnish an investor presentation by CEO Joseph C. Papa at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026. The company announced a restructuring plan expected to yield $40 million in annualized savings through workforce reductions of 90 roles and facility consolidations. Financially, Emergent reported MCM segment Q2 2026 revenue of $168 million and secured government contract modifications totaling approximately $117.2 million for ACAM2000® and BAT® products. The company also repurchased $75 million in unsecured bonds in the second quarter and reauthorized a $50 million share repurchase program with $37.5 million remaining. Full-year 2026 revenue guidance was revised downward to $645–$675 million, with adjusted EBITDA projected at $130–$150 million. Emergent BioSolutions Inc. operates in the biopharmaceutical industry, developing and manufacturing medical countermeasures for public health threats and opioid overdose treatments.